[1]崔 杰,刘 鑫.纤维蛋白原与白蛋白比值与激素受体阳性/人类表皮生长因子受体2阴性乳腺癌新辅助化疗疗效相关性分析[J].陕西医学杂志,2022,51(11):1351-1354,1359.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.007]
　CUI Jie,LIU Xin.Correlation between fibrinogen to albumin ratio and efficacy of neoadjuvant chemotherapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer[J].,2022,51(11):1351-1354,1359.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.007]
点击复制

纤维蛋白原与白蛋白比值与激素受体阳性/人类表皮生长因子受体2阴性乳腺癌新辅助化疗疗效相关性分析
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年11期
页码:
1351-1354,1359
栏目:
临床研究
出版日期:
2022-11-05

文章信息/Info

Title:
Correlation between fibrinogen to albumin ratio and efficacy of neoadjuvant chemotherapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer
作者:
崔 杰; 刘 鑫
(安康市中心医院,陕西 安康725000)
Author(s):
CUI Jie; LIU Xin
(Ankang Central Hospital,Ankang 725000,China)
关键词:
纤维蛋白原与白蛋白比值;  乳腺癌;  人类表皮生长因子受体2;  激素受体;  新辅助化疗
Keywords:
Fibrinogen to albumin ratio;  Breast cancer;  Human epidermal growth factor receptor 2;  Hormone receptor;  Neoadjuvant chemotherapy
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2022.11.007
文献标志码:
A
摘要:
目的:探讨纤维蛋白原与白蛋白比值(FAR)与激素受体阳性/人类表皮生长因子受体2阴性(HR+/HER2-)乳腺癌新辅助化疗(NAC)疗效的相关性。方法:回顾性分析112例首次实施NAC的HR+/HER2-乳腺癌患者的临床资料,首先绘制受试者工作特征(ROC)曲线确定FAR的最佳诊断截点值,并按照该值将患者分为高FAR组(≥0.073,n=38例)和低FAR组(<0.073,n=74例),采用卡方检验和秩和检验分析患者一般资料与NAC疗效的差异,采用多因素Logistic回归分析NAC疗效的相关因素。结果:FAR预测患者NAC疗效的ROC曲线下面积为0.719,最佳截断值为 0.073,灵敏度与特异度分别为78.97%和88.89%。与低FAR组比较,高FAR组雌激素受体(ER)、Ki-67高表达比例较低,两组比较差异有统计学意义(均P<0.05)。低FAR组NAC有效率显著高于高FAR组(82.43% 与 60.52%,P<0.05)。NAC有效患者平均FAR水平显著低于无效患者,两组比较差异有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,FAR≥0.073可能是HR+/HER2-乳腺癌患者NAC疗效的不良预测因素(OR=0.350,95%CI:0.224～0.542,P<0.05)。结论:FAR可能是预测HR+/HER2-乳腺癌患者NAC疗效的潜在指标,FAR<0.073的患者NAC疗效更佳。
Abstract:
Objective:To investigate the correlation between fibrinogen to albumin ratio(FAR)and the efficacy of neoadjuvant chemotherapy(NAC)for hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-)breast cancer.Methods:The clinical data of 112 HR+/HER2- breast cancer patients who underwent NAC for the first time were retrospectively analyzed.ROC curve was constructed to determine the optimal diagnostic cut-off value of FAR,and patients were categorized into high FAR group(≥0.073,38 cases)and low FAR group(<0.073,74 cases)according to that value.The chi-square test and log-rank test were used to analyze differences in general clinical data and NAC efficacy.Multivariate Logistic regression was used to analyze factors associated with the efficacy of NAR.Results:The area under the ROC curve for FAR to predict the efficacy of patients was 0.719,the optimal cut-off value was 0.073,and the sensitivity and specificity were 78.97% and 88.89%,respectively.Compared with the low FAR group,the proportion of estrogen receptor(ER)was higher in the high FAR group,and the proportion of high expression of Ki-67 was lower(all P<0.05).The efficiency of NAC in the low FAR group was significantly higher than that in the high FAR group(82.43% vs.60.52%,P<0.05).The mean FAR level in effective patients with NAC was significantly lower than that in ineffective patients(P<0.05).The results of multivariate Logistic regression analysis showed that FAR≥0.073 may be a poor predictor of NAC efficacy in patients with HR+/HER2- breast cancer(OR=0.350,95%CI:0.224 to 0.542,P<0.05).Conclusion:FAR may be a potential predictor of NAC efficacy in patients with HR+/HER2- breast cancer,and NAC efficacy is better in patients with FAR<0.073.

参考文献/References:

[1] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] 韩丕华,袁 权.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值[J].陕西医学杂志,2020,49(7):889-892.
[3] 沃眉宏,陆雨纯,靳 津,等.纤维蛋白原/前白蛋白比值和纤维蛋白原/白蛋白比值与早期糖尿病肾脏疾病患者肾小管损伤的相关性研究[J].中国糖尿病杂志,2021,29(12):896-901.
[4] 苑和平,赵源征,朱迎慧,等.纤维蛋白原与白蛋白比值对颈动脉粥样硬化不稳定斑块的预测价值[J].中华老年心脑血管病杂志,2020,22(11):1136-1139.
[5] 赵一品,季莹莹,王丰云,等.纤维蛋白原与白蛋白比值预测急性ST段抬高型心肌梗死患者梗死相关动脉自发再通的价值[J].中华心血管病杂志,2019,47(2):123-128.
[6] 张 磊,王黎昭,时飞宇,等.术前纤维蛋白原与血浆白蛋白比值与直肠癌患者预后的相关性分析[J].西安交通大学学报:医学版,2021,42(5):755-762.
[7] Cao X,Cui J,Yu T,et al.Fibrinogen/albumin ratio index is an independent prognosis predictor of recurrence-free survival in patients after surgical resection of gastrointestinal stromal tumors[J].Front Oncol,2020,65(10):1459-1468.
[8] Zhang Y,Xiao G.Prognostic significance of the ratio of fibrinogen and albumin in human malignancies:A meta-analysis[J].Cancer Manag Res,2019,53(11):3381-3393.
[9] Gallardo A,Garcia-Valdecasas B,Murata P,et al.Inverse relationship between Ki67 and survival in early luminal breast cancer:Confirmation in a multivariate analysis[J].Breast Cancer Res Treat,2018,167(1):31-37.
[10] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[11] 吴玉婷,朱 娅,左怀全.HR+/HER2-乳腺癌新辅助化疗疗效与影响因素分析[J].中国临床研究,2021,34(7):881-885.
[12] 牛志强,莱智勇,高 明,等.全身炎症反应指数评估消化系统恶性肿瘤患者预后的研究进展[J].国际外科学杂志,2021,48(2):132-136.
[13] 潘婉婉,董孟浩,余发智,等.外周血炎症指标NLR、PLR、LMR预测乳腺癌新辅助化疗疗效的价值[J].中华全科医学,2021,19(9):1442-1446.
[14] 李 锐,宋世博,李 强,等.术前纤维蛋白原与白蛋白比值对胆囊癌患者预后的影响[J].中华普通外科杂志,2020,35(2):142-145.
[15] Hwang KT,Chung JK,Roh EY,et al.Prognostic influence of preoperative fibrinogen to albumin ratio for breast cancer[J].J Breast Cancer,2017,20(3):254-263.
[16] 张宏旭,牛梦晔,张炳洲,等.术前中性粒细胞与淋巴细胞的比值和纤维蛋白原与白蛋白的比值对乳腺癌患者预后的影响[J].中华乳腺病杂志:电子版,2021,15(4):206-213.
[17] Jensen T,Kierulf P,Sandset PM,et al.Skjonsberg,fibrinogen and fifibrin induce synthesis of proinflflammatory cytokines from isolated peripheral blood mononuclear cells,thromb[J].Thromb Haemost,2007,97(5):822-829.
[18] Hou C,Jiang F,Ma H,et al.Prognostic role of preoperative platelet,fibrinogen,and d-dimer levels in patients with non-small cell lung cancer:A multicenter prospective study[J].Thorac Cancer,2019,10(2):304-311.
[19] Zheng S,Shen J,Jiao Y,et al.Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity[J].Cancer Sci,2009,100(5):859-865.
[20] 郑丽华,刘 峰,李 卫,等.白蛋白与纤维蛋白原比值与乳腺癌患者总生存期的关系[J].肿瘤防治研究,2020,47(2):102-107.

相似文献/References:

[1]王 敏,李习平,杨 梅,等.Caspase信号途径及其在乳腺癌治疗中的作用研究进展[J].陕西医学杂志,2021,50(3):377.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.032]
　WANG Min,LI Xiping,YANG Mei,et al.Research progress on Caspase signaling pathway and its role in treatment of breast cancer[J].,2021,50(11):377.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.032]
[2]陈丽丽,施民新,薛丽娟.剪接因子3B亚单位1在乳腺癌组织中的表达及与患者临床病理特征关系[J].陕西医学杂志,2024,(2):262.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.025]
　CHEN Lili,SHI Minxin,XUE Lijuan.Expression of SF3B1 in breast cancer tissues and its relationship with clinicopathology[J].,2024,(11):262.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.025]

更新日期/Last Update: 2022-11-09